Insulet Corporation (PODD) Stock Price & How to Invest

Insulet Corporation sells one thing extremely well. The Omnipod is a small adhesive pod worn on the body that holds insulin and delivers it without tubing, controlled by a phone app or a handheld. The current generation, Omnipod 5, is an automated insulin delivery system: it reads a continuous glucose monitor (Dexcom G7 or Abbott's FreeStyle Libre) and adjusts basal insulin automatically. The pods are disposable and replaced every three days, so the business is a classic razor-and-blade model where each new user converts into a predictable multi-year consumable stream. Insulet also distributes most of its US volume through the pharmacy channel rather than durable medical equipment, which lowers the friction of getting a patient started and has been a structural advantage over tubed competitors. A small drug delivery segment supplies pod technology to a pharmaceutical partner, but it is under ~2% of revenue and shrinking by design.

The financial profile is unusual for medtech: revenue reached ~$2.7 billion in 2025 and ~$3.05 billion on a trailing twelve-month basis by mid-2026, growing in the low-to-mid twenties percent, with adjusted gross margin near ~73% and adjusted operating margin around ~19%. Growth has come from three places at once: converting people with type 1 diabetes off injections, expanding internationally where Omnipod 5 launched much later than in the US, and the 2024 US label expansion into type 2 diabetes, which opened a population several times larger than type 1. That third leg is where the story cracked in August 2026. Insulet disclosed that type 2 users are dropping off at meaningfully higher rates than type 1 users, mostly inside the first 90 days, and cut its full-year US growth outlook. The shares fell about 20% in a day and sit roughly 60% below their 52-week high, which repriced the stock from a premium growth multiple to something closer to ~19x forward earnings. The debate now is whether type 2 attrition is a fixable onboarding and support problem or a signal that the addressable market is narrower than the label implies.

Type 2 retention is the live risk and the reason the shares derated: if attrition inside the first 90 days does not improve, the largest piece of the long-term growth story shrinks, and management's preliminary 2027 view of only mid-teens constant-currency growth already assumes no benefit from the fixes. Concentration is structural, since one product family is effectively the entire company and any manufacturing, supply or reimbursement disruption hits all of revenue at once. Competition is intensifying from Tandem's Mobi, Medtronic's MiniMed 780G, Beta Bionics and Sequel, and CGM partners Dexcom and Abbott are both suppliers and potential rivals as the category converges. GLP-1 adoption is an unquantified swing factor for the insulin-intensive type 2 population that Insulet is counting on. Finally, the stock carries growth-stock beta: it lost more than half its value from the 52-week high on a guidance cut that was small in dollar terms, which is how the market prices a business valued on its growth rate.

24 analysts publish price targets on PODD, averaging $235.54 against a $133.26 price as of August 2026, or +76.8%. The published targets run from $172.00 to $360.00, a wide spread, and the ratings split 21 buy, 4 hold, 0 sell. Over the last six months there has been 1 raise and 10 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full PODD forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Insulet Corporation. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Installed base compounding through pods. Every new Omnipod user becomes a recurring consumable customer who buys pods indefinitely, so revenue is far less dependent on new-unit sales than a durable device business. The most optimistic published target, $360.00, assumes this works close to its best case.

The case against. Type 2 retention is the live risk and the reason the shares derated: if attrition inside the first 90 days does not improve, the largest piece of the long-term growth story shrinks, and management's preliminary 2027 view of only mid-teens constant-currency growth already assumes no benefit from the fixes. The most pessimistic target, $172.00, is roughly what PODD is worth if this bites instead.

Read the full bull and bear case on PODD, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Insulet Corporation's investor relations page or your broker.

• Revenue (TTM): ~$3.05B
• Q2 2026 revenue: ~$802M, up ~23% year over year
• Adjusted gross margin (Q2 2026): ~72.9%
• Net income / EPS (TTM, GAAP): ~$375M / ~$5.35
• Free cash flow (TTM): ~$294M
• Market cap / valuation: ~$9.2B, ~25x trailing and ~19x forward earnings

Insulet guided full-year 2026 revenue to roughly $3.2-3.3 billion with constant-currency growth of ~20-22%, trimmed from ~21-23%, and cut US Omnipod growth to ~17-19% while raising international to ~30-32%. The cut was small in dollars but changed the narrative, and the shares fell about 20% on August 5, 2026 to around $133 against a 52-week high of ~$355. At roughly 19x forward earnings the stock now prices in materially slower growth than it did a year earlier.

Other names that sit close to PODD: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get PODD exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so PODD sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where PODD fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

PODD is a single-product medtech compounder with an unusually clean consumable revenue model, priced on how fast that installed base grows rather than on what it earns today.

Whether PODD is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is PODD a buy or a sell?, and where the stock could go from here in the PODD stock forecast.

For income investors, whether PODD pays a dividend and how the payout looks is covered in does PODD pay a dividend? And to weigh PODD against a peer, read the full side-by-side comparisons: PODD vs TNDM and PODD vs MDT.